Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) have been assigned a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $6.57.

TTPH has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Tetraphase Pharmaceuticals in a research report on Monday, July 16th. Piper Jaffray Companies dropped their target price on shares of Tetraphase Pharmaceuticals to $6.00 and set an “overweight” rating for the company in a research report on Thursday, October 11th. WBB Securities upgraded shares of Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Thursday, September 6th. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Finally, ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 30th.

Shares of Tetraphase Pharmaceuticals stock opened at $2.23 on Friday. The stock has a market cap of $122.63 million, a P/E ratio of -0.85 and a beta of 2.57. Tetraphase Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $6.97.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.18. The business had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $2.23 million. Tetraphase Pharmaceuticals had a negative net margin of 421.64% and a negative return on equity of 67.34%. Analysts expect that Tetraphase Pharmaceuticals will post -1.4 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the business. Flagship Harbor Advisors LLC bought a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth about $104,000. Canada Pension Plan Investment Board bought a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth about $179,000. UBS Group AG bought a new stake in Tetraphase Pharmaceuticals during the 1st quarter worth about $1,130,000. Bank of New York Mellon Corp grew its holdings in Tetraphase Pharmaceuticals by 20.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 289,970 shares of the biopharmaceutical company’s stock worth $1,035,000 after acquiring an additional 49,332 shares during the last quarter. Finally, Royce & Associates LP bought a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth about $556,000. 40.93% of the stock is currently owned by hedge funds and other institutional investors.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Further Reading: Calculate Your Return on Investment (ROI)

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.